Literature DB >> 20842456

Contribution of CDKN2A/P16 ( INK4A ), P14 (ARF), CDK4 and BRCA1/2 germline mutations in individuals with suspected genetic predisposition to uveal melanoma.

B Buecher1, M Gauthier-Villars, L Desjardins, L Lumbroso-Le Rouic, C Levy, A De Pauw, J Bombled, C Tirapo, C Houdayer, B Bressac-de Paillerets, D Stoppa-Lyonnet.   

Abstract

Uveal melanoma arises from melanocytes of the uveal tract (iris, ciliary body and choroid) and represents the most common intraocular malignancy in adults. Some rare clinical situations (young age at diagnosis, bilateral or multifocal forms, association with cutaneous malignant melanoma and/or familial aggregations of melanomas) are suggestive of genetic susceptibility. The aim of this study was to evaluate the contribution of CDKN2A/P16INK4A, P14ARF and CDK4 gene germline mutations in a series of patients with uveal melanoma recruited in a single institution with a clinical presentation indicative of genetic predisposition. Molecular analyses were proposed to 36 patients and were performed in 25 cases. The contribution of BRCA1/2 gene germline mutations in patients with uveal melanoma and a personal and/or family history of breast/ovarian cancers was also evaluated. Molecular analysis of BRCA1/2 genes was proposed to 35 patients and was performed in 25 patients. No deleterious germline mutation was identified in either group of patients. These results indicate that the CDKN2A/P16INK4A, P14ARF, CDK4 genes are not responsible for the vast majority of genetic susceptibility to uveal melanoma. They also suggest that one case of uveal melanoma in a family with a history of breast cancer is not sufficient to justify BRCA1/2 genetic testing when the classical criteria for molecular analysis are not present. International studies are ongoing in melanoma-prone families in an attempt to identify uveal melanoma susceptibility loci and genes.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20842456     DOI: 10.1007/s10689-010-9379-9

Source DB:  PubMed          Journal:  Fam Cancer        ISSN: 1389-9600            Impact factor:   2.375


  28 in total

1.  Rapid detection of novel BRCA1 rearrangements in high-risk breast-ovarian cancer families using multiplex PCR of short fluorescent fragments.

Authors:  Federica Casilli; Zorika Christiana Di Rocco; Sophie Gad; Isabelle Tournier; Dominique Stoppa-Lyonnet; Thierry Frebourg; Mario Tosi
Journal:  Hum Mutat       Date:  2002-09       Impact factor: 4.878

2.  Promoter hypermethylation: a common cause of reduced p16(INK4a) expression in uveal melanoma.

Authors:  P A van der Velden; J A Metzelaar-Blok; W Bergman; H Monique; H Hurks; R R Frants; N A Gruis; M J Jager
Journal:  Cancer Res       Date:  2001-07-01       Impact factor: 12.701

3.  Germline brca2 sequence variants in patients with ocular melanoma.

Authors:  O M Sinilnikova; K M Egan; J L Quinn; L Boutrand; G M Lenoir; D Stoppa-Lyonnet; L Desjardins; C Levy; D Goldgar; E S Gragoudas
Journal:  Int J Cancer       Date:  1999-07-30       Impact factor: 7.396

4.  Germline mutations in the p16INK4a binding domain of CDK4 in familial melanoma.

Authors:  L Zuo; J Weger; Q Yang; A M Goldstein; M A Tucker; G J Walker; N Hayward; N C Dracopoli
Journal:  Nat Genet       Date:  1996-01       Impact factor: 38.330

5.  Cancer risks in BRCA2 mutation carriers.

Authors: 
Journal:  J Natl Cancer Inst       Date:  1999-08-04       Impact factor: 13.506

6.  Analysis of p16 (CDKN2/MTS-1/INK4A) alterations in primary sporadic uveal melanoma.

Authors:  S L Merbs; D Sidransky
Journal:  Invest Ophthalmol Vis Sci       Date:  1999-03       Impact factor: 4.799

7.  Contribution of germline mutations in BRCA2, P16(INK4A), P14(ARF) and P15 to uveal melanoma.

Authors:  Nicholas Hearle; Bertil E Damato; Jane Humphreys; Julie Wixey; Helen Green; Joanne Stone; Douglas F Easton; Richard S Houlston
Journal:  Invest Ophthalmol Vis Sci       Date:  2003-02       Impact factor: 4.799

8.  Bilateral primary uveal melanoma. Bad luck or bad genes?

Authors:  A D Singh; C L Shields; J A Shields; P De Potter
Journal:  Ophthalmology       Date:  1996-02       Impact factor: 12.079

9.  Oncogenic mutations in GNAQ occur early in uveal melanoma.

Authors:  Michael D Onken; Lori A Worley; Meghan D Long; Shenghui Duan; M Laurin Council; Anne M Bowcock; J William Harbour
Journal:  Invest Ophthalmol Vis Sci       Date:  2008-08-21       Impact factor: 4.799

10.  Individuals with presumably hereditary uveal melanoma do not harbour germline mutations in the coding regions of either the P16INK4A, P14ARF or cdk4 genes.

Authors:  N Soufir; B Bressac-de Paillerets; L Desjardins; C Lévy; J Bombled; I Gorin; P Schlienger; D Stoppa-Lyonnet
Journal:  Br J Cancer       Date:  2000-02       Impact factor: 7.640

View more
  10 in total

1.  Evaluation of the contribution of germline variants in BRCA1 and BRCA2 to uveal and cutaneous melanoma.

Authors:  Peter A Johansson; Vaishnavi Nathan; Lauren M Bourke; Jane M Palmer; Tongwu Zhang; Judith Symmons; Madeleine Howlie; Ann-Marie Patch; Jazlyn Read; Elizabeth A Holland; Helen Schmid; Sunil Warrier; William Glasson; Veronica Höiom; Karin Wadt; Göran Jönsson; Håkan Olsson; Christian Ingvar; Graham Mann; Kevin M Brown; Nicholas K Hayward; Antonia L Pritchard
Journal:  Melanoma Res       Date:  2019-10       Impact factor: 3.599

2.  Germline BAP1 mutation predisposes to uveal melanoma, lung adenocarcinoma, meningioma, and other cancers.

Authors:  Mohamed H Abdel-Rahman; Robert Pilarski; Colleen M Cebulla; James B Massengill; Benjamin N Christopher; Getachew Boru; Peter Hovland; Frederick H Davidorf
Journal:  J Med Genet       Date:  2011-09-22       Impact factor: 6.318

3.  Analysis of BAP1 Germline Gene Mutation in Young Uveal Melanoma Patients.

Authors:  Colleen M Cebulla; Elaine M Binkley; Robert Pilarski; James B Massengill; Karan Rai; David A Liebner; Meghan J Marino; Arun D Singh; Mohamed H Abdel-Rahman
Journal:  Ophthalmic Genet       Date:  2015-02-17       Impact factor: 1.803

Review 4.  Genes and genetics in eye diseases: a genomic medicine approach for investigating hereditary and inflammatory ocular disorders.

Authors:  Mahavir Singh; Suresh C Tyagi
Journal:  Int J Ophthalmol       Date:  2018-01-18       Impact factor: 1.779

Review 5.  Genetics of primary intraocular tumors.

Authors:  Nisha Nagarkatti-Gude; Yujuan Wang; Mohammad Javed Ali; Santosh G Honavar; Martine J Jager; Chi-Chao Chan
Journal:  Ocul Immunol Inflamm       Date:  2012-08       Impact factor: 3.070

6.  3'UTR-CDKN2A and CDK4 Germline Variants Are Associated With Susceptibility to Cutaneous Melanoma.

Authors:  David Tovar-Parra; Sebastián Ramiro Gil-Quiñones; John Nova; Luz D Gutiérrez-Castañeda
Journal:  In Vivo       Date:  2021 May-Jun       Impact factor: 2.155

7.  Germline BAP1 inactivation is preferentially associated with metastatic ocular melanoma and cutaneous-ocular melanoma families.

Authors:  Ching-Ni Jenny Njauw; Ivana Kim; Adriano Piris; Michele Gabree; Michael Taylor; Anne Marie Lane; Margaret M DeAngelis; Evangelos Gragoudas; Lyn M Duncan; Hensin Tsao
Journal:  PLoS One       Date:  2012-04-24       Impact factor: 3.240

8.  Genetic markers of pigmentation are novel risk loci for uveal melanoma.

Authors:  Robert Ferguson; Matjaz Vogelsang; Esma Ucisik-Akkaya; Karan Rai; Robert Pilarski; Carlos N Martinez; Justin Rendleman; Esther Kazlow; Khagay Nagdimov; Iman Osman; Robert J Klein; Frederick H Davidorf; Colleen M Cebulla; Mohamed H Abdel-Rahman; Tomas Kirchhoff
Journal:  Sci Rep       Date:  2016-08-08       Impact factor: 4.379

9.  Advanced choroidal melanoma with a desirable aesthetic outcome after enucleation: A case report.

Authors:  Chryssa Terzidou; Alexandra Trivli; Georgios Dalianis; Dimitra Apessou; Demetrios A Spandidos; George N Goulielmos
Journal:  Oncol Lett       Date:  2018-05-08       Impact factor: 2.967

Review 10.  CRISPR/Cas9-A Promising Therapeutic Tool to Cure Blindness: Current Scenario and Future Prospects.

Authors:  Irshad Ahmad
Journal:  Int J Mol Sci       Date:  2022-09-29       Impact factor: 6.208

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.